|
gptkbp:instanceOf
|
antidepressant
selective serotonin reuptake inhibitor
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
1989
|
|
gptkbp:ATCCode
|
N06AB04
|
|
gptkbp:availableOn
|
gptkb:tablet
oral solution
|
|
gptkbp:bioavailability
|
80%
|
|
gptkbp:brand
|
gptkb:Celexa
gptkb:Cipramil
gptkb:Seropram
|
|
gptkbp:CASNumber
|
59729-33-8
|
|
gptkbp:chemicalFormula
|
C20H21FN2O
|
|
gptkbp:contraindication
|
QT prolongation
concurrent use with MAOIs
|
|
gptkbp:developedBy
|
gptkb:Lundbeck
|
|
gptkbp:eliminationHalfLife
|
35 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Citalopram
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:NSAIDs
gptkb:triptans
gptkb:CYP2C19_inhibitors
gptkb:St_John's_Wort
gptkb:tramadol
lithium
CYP3A4 inhibitors
other serotonergic drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
324.4 g/mol
|
|
gptkbp:patentExpired
|
2003
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
C (US)
|
|
gptkbp:proteinBinding
|
50%
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
hyponatremia
withdrawal symptoms
QT interval prolongation
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
insomnia
dry mouth
sexual dysfunction
somnolence
increased sweating
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
anxiety disorders
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|